The relation between atopic dermatitis and depressive symptoms
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2022.185299Keywords:
Atopic eczema, Atopic dermatitis, Depression, Depressive symptomsAbstract
ABSTRACT
Atopic dermatitis (AD) is characterized by chronic itching, presenting with fluctuating evolution, resulting in sleep disorders and social stigmatization due to the presence of visible and recurrent lesions, that might become progressively lichenified. Factors such as those mentioned and others associated, such as incapacity for work, lack of concentration throughout the day and isolation have profound impacts on the patient's mental health, resulting in low self-esteem, depression and frustration. In addition, it is known that AD is essentially an inflammatory disease. And, recent studies demonstrate the role of inflammatory cytokines in the development of depressive syndromes, therefore may be a causal correlation between the conditions by inflammatory pathways. Objectives: This systematic literature review aimed to analyze a relationship between atopic dermatitis and depressive symptoms, identifying mechanisms responsible for this connection. Methods: The research was carried out between 11/17/2020 and 11/18/2020 following the PRISMA model and using PUBMED, Virtual Health Library (VHL) - IBECS, LILACS and CUMED - and EMBASE databases. Keywords “Depression” and “Atopic Eczema”, along with its MeSh and DECS terms, were used and associated using the Boolean method. Inclusion criteria were defined as articles that are clinical or observational trials involving a group of patients with atopic dermatitis and a control group, which could be constituted by the group with atopic dermatitis itself, however, after an intervention. The depressive symptoms had to be measured by scales or, at least, the criteria for diagnosis of depressed syndrome must have been established. Results: In the end, fifteen studies remained, which were classified among those that compare treatments and their outcomes related to depression and AD, those that propose AD as an aggravator of depressive symptoms, those that propose depressive symptoms as an aggravating factor for AD and those that bring statistical analysis without clearly establishing where the causality relation resides. Conclusion: Several studies have presented a relationship between the condition of AD and depressive symptoms in distinct pathways, or analyzing AD as an aggravating factor for depressive symptoms or vice-versa. From this perspective, there may be a cyclical bidirectional causality, in which constant positive feedback generates worsening of both conditions until the adequate approach is taken, highlighting the importance of the multidisciplinary propaedeutics for these patients.
Downloads
References
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019 Dec;46(12):1053-1101. doi: 10.1111/1346-8138.15090. Epub 2019 Oct 9. PMID: 31599013.
Nørreslet LB, Ebbehøj NE, Ellekilde Bonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life - a systematic review. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):23–38. http://dx.doi.org/10.1111/jdv.14523
Carroll CL, Balkrishnan R, Feldman SR, Fleischer ABJ, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–9. http://dx.doi.org/10.1111/j.1525-1470.2005.22303.x
Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, Luger TA, Deleuran M, Werfel T, Eyerich K, Stingl G; Councilors of the International Eczema Council. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. J Invest Dermatol. 2017 Jan;137(1):18-25. doi: 10.1016/j.jid.2016.08.022. Epub 2016 Oct 20. PMID: 27771048.
Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013 Jul;31:105-14. doi: 10.1016/j.bbi.2012.12.008. Epub 2012 Dec 20. PMID: 23261775; PMCID: PMC4426992.
Alcocer-Gómez E, de Miguel M, Casas-Barquero N, Núñez-Vasco J, Sánchez-Alcazar JA, Fernández-Rodríguez A, Cordero MD. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun. 2014 Feb;36:111-7. doi: 10.1016/j.bbi.2013.10.017. PMID: 24513871.
Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun. 2014 Nov;42:50-9. doi: 10.1016/j.bbi.2014.05.007. Epub 2014 May 20. PMID: 24858659.
Schonmann Y, Mansfield KE, Hayes JF, Abuabara K, Roberts A, Smeeth L, et al. Atopic Eczema in Adulthood and Risk of Depression and Anxiety: A Population-Based Cohort Study. J allergy Clin Immunol Pract. 2020 Jan;8(1):248-257.e16. http://dx.doi.org/10.1016/j.jaip.2019.08.030
Associação Americana de Psiquiatria. Manual Diagnóstico e Estatístico de Transtornos Mentais. 5th ed. Porto Alegre-RS: Artmed; 1994.
McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388-396. doi: 10.1001/jama.2017.19163. Erratum in: JAMA. 2019 Nov 26;322(20):2026. PMID: 29362800.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898. PMID: 31462531.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sep;25(9):603-5. doi: 10.1007/s10654-010-9491-z. Epub 2010 Jul 22. PMID: 20652370.
Arima M, Shimizu Y, Sowa J, Narita T, Nishi I, Iwata N, et al. Psychosomatic analysis of atopic dermatitis using a psychological test. J Dermatol. 2005 Mar;32(3):160–8. http://dx.doi.org/10.1111/j.1346-8138.2005.tb00738.x
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015 Apr;135(4):984–91. http://dx.doi.org/10.1038/jid.2014.530
Zachariae R, Lei U, Haedersdal M, Zachariae C. Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale. Acta Derm Venereol. 2012 Sep;92(5):508-14. doi: 10.2340/00015555-1221. PMID: 22002738.
Brenaut E, Halvorsen JA, Dalgard FJ, Lien L, Balieva F, Sampogna F, et al. The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):157–62. http://dx.doi.org/10.1111/jdv.15145
Lind N, Nordin M, Palmquist E, Nordin S. Psychological distress in asthma and allergy: the Västerbotten Environmental Health Study. Psychol Health Med. 2014;19(3):316–23. http://dx.doi.org/10.1080/13548506.2013.806814
Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, et al. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. JAMA dermatology. 2018 Aug;154(8):903–12. http://dx.doi.org/10.1001/jamadermatol.2018.1572
Sicras-Mainar A, Navarro-Artieda R, Carrascosa Carrillo JM. Economic Impact of Atopic Dermatitis in Adults: A Population-Based Study (IDEA Study). Actas Dermosifiliogr. 2018 Jan-Feb;109(1):35-46. English, Spanish. doi: 10.1016/j.ad.2017.09.003. Epub 2017 Nov 8. PMID: 29126499.
Poot F, Antoine E, Gravellier M, Hirtt J, Alfani S, Forchetti G, et al. A Case-control Study on Family Dysfunction in Patients with Alopecia Areata, Psoriasis and Atopic Dermatitis. Acta Derm Venereol [Internet]. 2011 Jun;91(4):415–21. http://dx.doi.org/10.2340/00015555-1074
Kim S-H, Hur J, Jang J-Y, Park H-S, Hong CH, Son SJ, et al. Psychological Distress in Young Adult Males with Atopic Dermatitis: A Cross-Sectional Study. Medicine (Baltimore). 2015 Jun;94(23):e949. http://dx.doi.org/ 10.1097/MD.0000000000000949.
Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019 Jul;81(1):187–95. http://dx.doi.org/10.1016/j.jaad.2019.03.037
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020 Sep;31(6):606–14. http://dx.doi.org/10.1080/09546634.2019.1612836
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical . Br J Dermatol. 2018 May;178(5):1083–101. http://dx.doi.org/10.1111/bjd.16156
Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol [Internet]. 2016 Sep;75(3):506–15. http://dx.doi.org/10.1016/j.jaad.2016.04.054
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med [Internet]. 2016 Dec 15;375(24):2335–48. http://dx.doi.org/10.1056/NEJMoa1610020
Hedman-Lagerlöf E, Bergman A, Lindefors N, Bradley M. Exposure-based cognitive behavior therapy for atopic dermatitis: an open trial. Cogn Behav Ther. 2019 Jul;48(4):300–10. http://dx.doi.org/10.1080/16506073.2018.1504320
Consensus Report of the European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186(1):23–31. http://dx.doi.org/10.1159/000247298
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet [Internet]. 2006;367(9504):29–35. http://dx.doi.org/10.1016/S0140-6736(05)67763-X
Svanborg P, Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand. 1994 Jan;89(1):21–8. http://dx.doi.org/10.1111/j.1600-0447.1994.tb01480.x
Hashizume H., Takigawa M. Interventional stress management for atopic dermatitis. Jpn J Dermatol. 2004;(114):959–966. http://dx.doi.org/10.14924/dermatol.114.959
Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol. 2011 Aug 5;11(9):625-32. doi: 10.1038/nri3042. PMID: 21818124; PMCID: PMC3597082.
Pan Y, Chen XY, Zhang QY, Kong LD. Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats. Brain Behav Immun. 2014 Oct;41:90-100. doi: 10.1016/j.bbi.2014.04.007. Epub 2014 May 22. PMID: 24859041.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016 Jan;16(1):22-34. doi: 10.1038/nri.2015.5. PMID: 26711676; PMCID: PMC5542678.
Felger JC, Lotrich FE. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience. 2013. http://dx.doi.org/10.1016/j.neuroscience.2013.04.060
Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009 Aug;66(3):287–92. http://dx.doi.org/10.1016/j.biopsych.2009.01.030
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Marcelo Alcântara de Passos Junior, Alécio Vinícius Sá Gomes e Farias, Gean dos Reis Antunes, Marcos Vinicius Maceno e Silva, Tânia Rita Moreno de Oliveira Fernandes
This work is licensed under a Creative Commons Attribution 4.0 International License.
